Clinical research and medical treatment are often confused for one another, leading drug companies and healthcare professionals to risk falling out of compliance.
As more states move to decriminalize cannabis, the regulatory framework becomes more complicated. How can companies successfully navigate federal and state laws?
Drug manufacturers developing OTC drugs have a lot of important decisions to make. One of these decisions is determining which regulatory pathway works best for their product.
There is growing pressure from patients to make healthcare more transparent. However, there remain privacy concerns about publicizing clinical research data.
The FDA issued warning letters to several CBD companies for selling unapproved products with unsubstantiated medical claims.
How can you ensure readiness and compliance for FDA inspections? It is important for companies to investigate who the FDA targets, and how, to make sure they follow regulations.